Taiwan Liposome Company Ltd. (TLC) and Bioblast Pharma Ltd. (NASDAQ:ORPN) Comparing side by side

We are comparing Taiwan Liposome Company Ltd. (NASDAQ:TLC) and Bioblast Pharma Ltd. (NASDAQ:ORPN) on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Taiwan Liposome Company Ltd. N/A 0.00 N/A -0.51 0.00
Bioblast Pharma Ltd. N/A 0.00 3.33M -1.00 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Taiwan Liposome Company Ltd. and Bioblast Pharma Ltd.


Table 2 has Taiwan Liposome Company Ltd. and Bioblast Pharma Ltd.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Taiwan Liposome Company Ltd. 0.00% 0% 0%
Bioblast Pharma Ltd. 0.00% -101.1% -88.2%

Institutional & Insider Ownership

Institutional investors owned 2.46% of Taiwan Liposome Company Ltd. shares and 19.5% of Bioblast Pharma Ltd. shares. Comparatively, Bioblast Pharma Ltd. has 36.85% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Taiwan Liposome Company Ltd. -0.5% -2.14% -6.74% 0% 0% 8.18%
Bioblast Pharma Ltd. -6.62% 15.98% -2.31% 0.79% -50.58% 64.13%

For the past year Taiwan Liposome Company Ltd.’s stock price has smaller growth than Bioblast Pharma Ltd.


On 4 of the 6 factors Taiwan Liposome Company Ltd. beats Bioblast Pharma Ltd.

Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. It develops Trehalose 90mg/mL IV solution, a protein stabilizer and autophagy enhancer to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company was founded in 2012 and is headquartered in Tel Aviv, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.